Ropivacaine (mesylate)

Ropivacaine mesylate is a long-acting amide local anaesthetic agent for a spinal block and effectively blocks neuropathic pain. Ropivacaine blocks impulse conduction via reversible inhibition of sodium ion influx in nerve fibressup>[1][2]. Ropivacaine is also an inhibitor of K2P (two-pore domain potassium channel) TREK-1 with an IC50 of 402.7 μM in COS-7 cell's membrane[3].

Product Specifications

CAS Number

[854056-07-8]

UNSPSC

12352005

Hazard Statement

H302, H315, H319, H335

Target

Potassium Channel; Sodium Channel

Type

Reference compound

Related Pathways

Membrane Transporter/Ion Channel

Applications

COVID-19-immunoregulation

Field of Research

Neurological Disease; Cardiovascular Disease; Cancer

Assay Protocol

https://www.medchemexpress.com/ropivacaine-mesylate.html

Purity

99.51

Solubility

H2O : 250 mg/mL (ultrasonic)

Smiles

O=C([C@H]1N(CCC)CCCC1)NC2=C(C)C=CC=C2C.CS(=O)(O)=O

Molecular Formula

C18H30N2O4S

Molecular Weight

370.51

Precautions

H302, H315, H319, H335

References & Citations

[1]Li TF, et al. Epidural sustained release ropivacaine prolongs anti-allodynia and anti-hyperalgesia in developing and established neuropathic pain. PLoS One. 2015 Jan 24;10 (1) :e0117321.|[2]Milan Patel, et al. Ropivacaine Inhibits Pressure-Induced Lung Endothelial Hyperpermeability in Models of Acute Hypertension. Life Sci. 2019 Apr 1;222:22-28.|[3]Dene Simpson, et al. Ropivacaine: a review of its use in regional anaesthesia and acute pain management. Drugs. 2005;65 (18) :2675-717.|[4]Hye Won Shin, et al. The inhibitory effects of bupivacaine, levobupivacaine, and ropivacaine on K2P (two-pore domain potassium) channel TREK-1. J Anesth. 2014 Feb;28 (1) :81-6.